Mifamurtide

Phase 2Peptide

Takeda

Mifamurtide is one of 46 small molecule programs targeting Osteosarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteosarcomaActive, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Osteosarcoma

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

4 2

Trexall

Jazz Pharmaceuticals

Phase 3

17 3

Verzenio

Adriamycin

10 5

Lithobid

SSolvay Pharmaceuticals

Approved

1 6

Ifex

BBaxter Healthcare Corporation

Phase 3

18 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

17 8

Paraplatin

AAvyxa

Approved

—9

Rapamune

PPrism Pharmaceuticals

Vepesid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2033

Phase 2Recruiting

Osteosarcoma

NCT07787429

Q4 2033

Phase 2Active, not recruiting

Osteosarcoma

NCT03643133

Clinical

Trials by Indication[1]

Osteosarcoma5 trials

Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

Active, not recruiting·UUNICANCER·Phase 2·NCT03643133·60 enrolled

Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

Terminated· Takeda logo

Takeda··NCT01194284·25 enrolled

A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)

Terminated·UUniversity of Oxford·Phase 2·NCT02441309·8 enrolled

Show 2 more trials

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

Completed· Takeda logo

Takeda··NCT00631631·205 enrolled

Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma (DRAGONFLY)

Recruiting·AAnna Raciborska·Phase 2·NCT07787429·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Mifamurtide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mifamurtide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mifamurtide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: Takeda

Mifamurtide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2033

Q4 2033

Trials by Indication[1]

Osteosarcoma5 trials

References

Drug Info

Quick Facts

Related News